Patient-Reported Safety Information: A Renaissance of Pharmacovigilance? Linda HärmarkJune RaineAgnes Kant Current Opinion 04 October 2016 Pages: 883 - 890
Pacific Island Pharmacovigilance: The Need for a Different Approach John McEwenLasse S. VestergaardAmanda L. C. Sanburg Current Opinion 04 October 2016 Pages: 891 - 894
Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns Stephen A. Goldman Leading Article 04 October 2016 Pages: 895 - 901
Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects Irma ConvertinoAlice Capogrosso SansoneMarco Tuccori Review Article 04 October 2016 Pages: 903 - 924
Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions Mahmoud SlimInmaculada Medina-CalizRaul J. Andrade Review Article 04 October 2016 Pages: 925 - 943
Neuropsychiatric Effects of HIV Antiviral Medications Glenn J. TreismanOlivia Soudry Review Article 04 October 2016 Pages: 945 - 957
Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale Beth RachlisRakhi KarwaPaula Braitstein Original Research Article Open access 04 October 2016 Pages: 959 - 976
Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study Christian HoppePatrick ObermeierBarbara Rath Original Research Article 04 October 2016 Pages: 977 - 988
16th ISoP Annual Meeting ‘‘Pharmacovigilance for Safer Tomorrow’’ Agra, India 16–19 October, 2016 Abstracts 04 October 2016 Pages: 989 - 1042